Analyzing Astrazeneca PLC (AZN) and Its Peers
Astrazeneca PLC (NYSE: AZN) is one of 104 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Astrazeneca PLC to similar companies based on the strength of its analyst recommendations, institutional ownership, dividends, risk, earnings, valuation and profitability.
Valuation & Earnings
This table compares Astrazeneca PLC and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Astrazeneca PLC||$23.00 billion||$3.50 billion||24.09|
|Astrazeneca PLC Competitors||$8.17 billion||$1.09 billion||123.57|
Astrazeneca PLC has higher revenue and earnings than its competitors. Astrazeneca PLC is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
Astrazeneca PLC has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Astrazeneca PLC’s competitors have a beta of 39.14, indicating that their average share price is 3,814% more volatile than the S&P 500.
This is a breakdown of current recommendations and price targets for Astrazeneca PLC and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Astrazeneca PLC Competitors||863||3774||6742||178||2.54|
Astrazeneca PLC presently has a consensus target price of $36.60, suggesting a potential upside of 8.51%. As a group, “Pharmaceuticals” companies have a potential upside of 33.90%. Given Astrazeneca PLC’s competitors stronger consensus rating and higher possible upside, analysts plainly believe Astrazeneca PLC has less favorable growth aspects than its competitors.
Insider & Institutional Ownership
14.4% of Astrazeneca PLC shares are owned by institutional investors. Comparatively, 44.2% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 11.3% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This table compares Astrazeneca PLC and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Astrazeneca PLC Competitors||-458.15%||-54.27%||-6.38%|
Astrazeneca PLC pays an annual dividend of $1.37 per share and has a dividend yield of 4.1%. Astrazeneca PLC pays out 97.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Pharmaceuticals” companies pay a dividend yield of 2.5% and pay out 72.3% of their earnings in the form of a dividend.
Astrazeneca PLC competitors beat Astrazeneca PLC on 9 of the 15 factors compared.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.
Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.